Beam Therapeutics Inc. (BEAM) Balance Sheet

The accumulated deficit has deepened from about -$1.4B in 2024Q2 to -$2.0B in 2026Q3, which is consistent with sustained operating losses rather than a one-off charge. Total assets have also declined over the most recent quarters, indicating that the cash-consuming platform is shrinking its resource base without yet demonstrating a self-funding trajectory. Investors should monitor whether the equity decline accelerates, as it may signal increasing reliance on future financing.

Debt has remained in a relatively narrow band of roughly $151M to $294M across the ten quarters, which appears more consistent with lease and structured liabilities than with aggressive borrowing. Because total liabilities of $316.4M are not dominated by debt, the leverage risk appears moderate, but refinancing exposure cannot be fully assessed from these figures alone. The trend warrants further investigation into the maturity profile and the composition of the debt line.

The current ratio remains high, reflecting a large short-term asset base relative to short-term obligations, which suggests near-term solvency is not the primary concern. However, with cash declining from $527.9M in 2025Q1 to $213.3M in 2026Q3, the implied runway at the latest burn rate appears limited to a few quarters. Investors should monitor the pace of cash depletion relative to any non-dilutive collaboration inflows.

The absence of goodwill removes a common source of write-down risk, and the PPE balance, while meaningful, has been declining steadily from $224.3M in 2024Q2 to $187.0M, consistent with depreciation outpacing new capital investment. This pattern suggests the laboratory infrastructure is being used rather than expanded, which may limit manufacturing scale-up readiness. The asset mix therefore reflects a research platform rather than a commercial production base.